NCT00865228终止2 期
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia
Takeda0 个研究点目标入组 224 人开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 224
- 主要终点
- Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration
研究概览
简要总结
The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
详细描述
Dyslipidemias are a group of metabolic disorders produced by raised concentrations of lipoproteins, especially low-density lipoprotein cholesterol the lipoprotein that transports endogenous cholesterol from the liver to the peripheral tissues. Increased cholesterol and triglyceride levels lead to an increased risk of arteriosclerosis, the underlying cause of heart attack, strokes and peripheral vascular disease. Despite changes in lifestyle and the availability of potent lipid-lowering agents, cardiovascular disease continues to be the major cause of death in Western Europe and North America.
Lapaquistat acetate is being developed by Takeda for the treatment of hypercholesterolemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- •Has prior to Randomization a mean low-density lipoprotein cholesterol greater than or equal to 130 mg/dL and less than or equal to 220 mg/dL for 2 consecutive samples.
- •Has prior to Randomization mean triglycerides less than 400 mg/dL for 2 consecutive samples.
- •Is willing and able to comply with a standardized, therapeutic lifestyle change diet or equivalent.
排除标准
- •Has an alanine aminotransferase or aspartate aminotransferase level greater than 2 times the upper limit of normal during the screening period.
- •Has a serum creatinine greater than133 mmol/L during the screening period.
- •Has a creatine phosphokinase greater than 3 times the upper limit of normal, identified during the screening period.
- •Has active liver disease or jaundice.
- •Has a history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.
- •Has an endocrine disorder, such as Cushing syndrome, hyperthyroidism, or inappropriately treated hypothyroidism, affecting lipid metabolism.
- •Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdomin al aorticaneurysm, coronary angioplasty, coronary or peripheral arterial surgery or multiple risk factors that confer a 10-year risk for cardiovascular disease greater than 20% based on Framingham risk scoring.
- •Has a positive hepatitis B surface antigen, or antibody to hepatitis C virus, as determined by medical history and/or subject's verbal report.
- •Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
- •Has received any investigational compound within 30 days prior to screening Visit 1, or is currently participating in another investigational study.
- •Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.
- •Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.
- •Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia.
- •Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
- •Has uncontrolled hypertension despite treatment at Screening Visit
- •Has had inflammatory bowel or any other malabsorption syndrome or has had gastric bypass or any other surgical procedure for weight loss.
- •Has a history of drug abuse or alcohol abuse within the past 2 years.
- •Has stage I squamous cell carcinoma of the skin.
- •Has type 1 or type 2 diabetes mellitus.
- •Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- •Fluvastatin
- •Lovastatin
- •bile acid sequestrants (eg, cholestyramine)
- •intestinal cholesterol uptake inhibitors (eg, ezetimibe)
- •Fibrates (eg, fenofibrate, gemfibrozil)
- •Cholestin
- •red yeast rice
- •fish oils
- •plant sterols and stanols
- •sibutramine
- •isotretinoin
- •tacrolimus
- •Systemic corticosteroids and androgens
- •Potent CYP3A4 inhibitors
- •Cyclosporine
- •Erythromycin
- •Clarithromycin
- •Telithromycin
- •human immunodeficiency virus protease inhibitors
- •amiodarone
- •diltiazem
- •verapamil
- •nefazodone
- •grapefruit juice
研究组 & 干预措施
Lapaquistat Acetate 100 mg QD (morning)
Experimental
干预措施: Lapaquistat acetate (Drug)
Lapaquistat Acetate 100 mg QD (evening)
Experimental
干预措施: Lapaquistat acetate (Drug)
Lapaquistat Acetate 50 mg BID
Experimental
干预措施: Lapaquistat acetate (Drug)
Placebo BID
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration
时间窗: Week 6
次要结局
- Change from Baseline in Total Cholesterol(Week 6)
- Percent change from Baseline in apolipoprotein B(Week 6)
- Percent change from Baseline in apolipoprotein A1(Week 6)
- Change from Baseline in Triglycerides(Week 6)
- Percent change from Baseline in High-Density Lipoprotein Cholesterol(Week 6)
- Percent change from Baseline in Very Low-Density Lipoprotein Cholesterol(Week 6)
- Percent change from Baseline in non- High-Density Lipoprotein Cholesterol(Week 6)
- Percent change from Baseline in derived ratio of Low-Density Lipoprotein Cholesterol / High-Density Lipoprotein Cholesterol(Week 6)
- Percent change from Baseline in derived ratio of Total Cholesterol / High-Density Lipoprotein Cholesterol(Week 6)
- Percent change from Baseline in derived ratio of apolipoprotein B / apolipoprotein A1(Week 6)
- Change from Baseline in high sensitivity C-Reactive Protein.(Week 6)
研究者
相似试验
终止
3 期
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With HypercholesterolemiaHypercholesterolemiaNCT00532558Takeda657
已完成
3 期
A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)HypercholesterolemiaNCT00092651Organon and Co1,398
已完成
3 期
An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)HypercholesterolemiaNCT00092664Organon and Co1,104
已完成
2 期
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed DyslipidemiaDyslipidemiaNCT00245388Bristol-Myers Squibb330
已完成
3 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCoronary Heart Disease (CHD)NCT03872401Amgen12,301